

## Call for Abstracts

---

### General information

The EORTC Summit on Clinical Cancer Research 2027 welcomes abstracts addressing key challenges in clinical cancer research across its four thematic tracks. Abstracts should focus on how clinical cancer research is designed, conducted, evaluated, regulated or implemented.

Submissions from early-career investigators are particularly encouraged.

**Abstract submission open:**

**30 September 2026**

**Abstract submission deadline:**

**4 November 2026**

Abstracts submitted after the deadline will not be considered. Authors are strongly encouraged to submit prior to the deadline to allow time to resolve any technical or administrative issues.

In case of any abstract related queries, please contact: [sabien.dehanscutter@eortc.org](mailto:sabien.dehanscutter@eortc.org)

### Abstract topics

Authors should select the thematic track that best reflects the principal focus of the abstract:

- Data Science & Artificial Intelligence
- Quality of Life & Patient Centricity
- Methodology
- International Policy & Regulations

Examples may include innovative trial designs and statistical methods; data quality, interoperability and real-world data; artificial intelligence and machine learning in clinical research; patient-reported outcomes and patient engagement; decentralised or digitally enabled research; research efficiency and implementation; cross-border research; and regulatory or policy approaches shaping clinical cancer research. These examples are illustrative rather than exhaustive.

### Abstract policy and author responsibilities

By submitting an abstract to the EORTC Summit on Clinical Cancer Research 2027, the presenting author:

- Accepts responsibility for the accuracy of the submitted abstract.
- Accepts to be the contact person for all correspondence regarding the abstract and inform co-authors of its status.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.

- Confirms that the data and conclusions presented in the abstract have not been published or presented at any meeting prior to the EORTC Summit on Clinical Cancer Research 2027.
- Where previously presented data are included, ensures that the submission contains a material update, a distinct analysis, or a clearly different scientific or methodological contribution, and transparently identifies the relationship to the earlier presentation where requested.
- Confirms that the work was conducted in accordance with applicable ethical, legal and regulatory requirements.
- Discloses all relevant sources of funding and support for the work.
- Discloses for all authors any financial and non-financial relationships or activities that could reasonably be perceived as relevant to the submitted work.
- Discloses the use of generative artificial intelligence or other AI-assisted technologies in preparing the abstract or in the underlying research, where relevant. AI tools must not be listed as authors; human authors remain responsible for the accuracy, originality and integrity of the submission.
- Grants EORTC the permission to publish accepted abstract content on the EORTC Summit website and, where applicable and subject to the relevant publication terms, in an EORTC Summit supplement of the European Journal of Cancer.

## Abstract preparation and submission

- Abstracts must be submitted in **good English** and **carefully proofread** to ensure the accuracy of published material. The Scientific Committee reserves the right to reject abstracts submitted in poor English or may request language or editorial revisions when needed for clarity, consistency or publication quality.
- The **title of the abstract** should be concise, informative and accurately reflect the content. Do not use non-standard abbreviations and commercial names (generic names only).
- Abstracts should be structured to include the following **4 sections**:
  - **Background and objective:** briefly describe the problem or challenge and state the objective or question addressed.
  - **Approach / methods:** describe the design, data source(s), methodological or operational approach, population or setting, and analysis/evaluation methods, as relevant.
  - **Findings / results:** report the principal findings, evidence, performance measures or lessons learned. For conceptual, policy or methods-development submissions where empirical results are not applicable, clearly state the basis for the conclusions and the stage of development or evaluation.
  - **Conclusions and implications:** state the main conclusion and its implications for the design, conduct, evaluation, regulation or implementation of clinical cancer research. Conclusions must be supported by the information presented and should avoid overstatement.
- The abstract submission system will not accept abstracts **exceeding 2900 characters**, including spaces, the body of the abstract and one table.
- **A maximum of one data table** is permitted. Figures and other illustrations are not permitted and will be deleted if submitted except for structure formula.

- **References** should not be included unless the Scientific Committee decides that citations are required for policy/methodology submissions.
- **Abbreviations** should be limited to standard abbreviations. Other abbreviations must be written out in full at first use, followed by the abbreviation in parentheses.
- Use International Nonproprietary Names (INN)/generic names for medicines whenever possible. If a proprietary name is scientifically necessary, place it in parentheses after the generic name and use it only where needed for identification; promotional use of trade names is not permitted.
- Provide up to **3 keywords** to distinguish the abstract for indexing purposes.
- **A maximum of 20 authors** may be listed. Provide institutional affiliation(s), city and country for each author. Do not include academic degrees or full postal addresses. For collaborative groups or consortia, use a consistent group-authorship format and identify individual authors/contributors in accordance with the submission system requirements.

## Conflicts of interest and disclosures

**Disclosure requirements apply to all abstract authors.** The presenting/submitting author is responsible for obtaining disclosure information from all co-authors and entering it accurately in the submission system. Relevant financial and non-financial relationships and activities should be disclosed, whether or not the author believes they constitute a conflict of interest. Disclosures will be made publicly available in connection with the Summit and any abstract publication.

## Submission confirmation

An email confirming receipt of the online submission will be sent to the presenting author, normally within 48 hours. **The assigned abstract number should be quoted in all correspondence concerning the submission.**

## Abstract selection process

Abstracts submitted for the EORTC Summit on Clinical Cancer Research 2027 will be reviewed by an international panel with expertise relevant to the selected thematic track. Review will be based on the information contained in the submitted abstract. The final decision on the presentation format of all accepted abstracts lies at the sole discretion of the Scientific Committee.

Accepted abstracts will be presented as **posters**, displayed on boards in a prominent poster viewing area. Posters will be thematically grouped and exhibited for the duration of the EORTC Summit. Designated time slots will be allocated for poster viewing to support dialogue, critical exchange and networking across the clinical cancer research community.

A curated selection of high-quality posters may be featured in brief **“Poster-in-the-Spotlight”** oral presentations, followed by a moderated discussion. These sessions aim to promote engaging dialogue on selected findings of broad relevance. Selection for this format is at the discretion of the Scientific Committee.

## Publication and embargo

Accepted abstracts will be published on the EORTC Summit website two weeks before the event. Authors who do not wish their abstract to be made public at that time must notify the EORTC Summit Secretariat by the deadline stated in the acceptance notification. Where early online publication is declined, the abstract will be released on the first day of the Summit.

Where applicable and subject to the relevant publication terms, accepted abstracts will be published in an EORTC Summit supplement of the European Journal of Cancer.

## Registration and presenter obligations

Submitting an abstract for presentation in the EORTC Summit on Clinical Cancer Research 2027 does not constitute registration for the event. When selected, abstract presenters must register to attend the EORTC Summit on Clinical Cancer Research 2027 in Brussels.

**The presenting author** will receive the result of the review and the Scientific Committee's decision on their abstract by email **around mid-January 2027**.

## Abstract withdrawal

EORTC cannot guarantee any request for withdrawal of an abstract that in any way delays the publications. Requests to withdraw an abstract must be submitted in writing to the EORTC Summit Secretariat **by 1 February 2027**. EORTC cannot guarantee removal from publication materials once production deadlines have passed. After the withdrawal deadline, an accepted abstract is expected to be presented. If the designated presenting author cannot attend, another listed author should be nominated as presenter and the Secretariat informed as soon as possible.

## Data protection and sharing of contact details

This event is organised by EORTC.

To manage Participant's registration, abstract submission, and participation to this event, EORTC collects and stores Participant's personal data in order to promote and evaluate the event, and to produce statistics on participation to the events. Other personal information might be required in scope of organisation of travel and accommodation. Your personal data may be collected through forms we ask you to complete or through the website of EORTC or their partners and subcontractors. This can create opportunities that undertakings that have nothing to do with EORTC might use for phishing emails purposes; please be careful not to provide your personal data to these undertakings or in case of doubts, please do not hesitate to verify the validity of the request with the EORTC. Our legal basis for the processing of the Participant's data is contract execution (Participant's registration to our event, organisation of the travel and accommodation and abstract submission processing), legal compliance (e.g. accountancy) and legitimate interest (statistics of participation, evaluation of the event and event promotion). Please note that when processing is based on legitimate interest, you will still be able to exercise the right to object. Participant's name, specialty when relevant, organisation and country will appear on the event



badges. The processing of personal data collected falls under the EU General Data Protection Regulation 679/2016 (hereafter also “GDPR”, applicable as of 25/05/2018) and the Belgian Law of 30 July 2018 on the protection of natural persons with regard to the processing of personal data.

Participant’s data will be stored for a maximum of 10 years after the end of the event. After this period, EORTC will either anonymise or delete Participant’s personal information.

Please also read carefully the [EORTC Privacy Policy](#) to find out more about privacy and your data subject rights.

If Participants register for this event, and if consented (optional), EORTC may contact Participants occasionally to inform them about other EORTC events that may be of interest or provide them with more information about EORTC activities or other relevant information relative to cancer research, for example in the form of a newsletter. If Participants do not wish to receive information from EORTC in the future, and want to be removed from EORTC’s mailing list, they can unsubscribe from the mailing list, or write at any time to [events@eortc.org](mailto:events@eortc.org).

This event may include a photographer and may be recorded for promotional purposes only. These photos/recordings may be used in official EORTC press releases, printed and/or online publicity and published on any EORTC social media network, such as Facebook, Twitter, YouTube, or LinkedIn. EORTC will delete them after they are no longer needed for publicity purposes. To be removed from any EORTC online or offline publication please contact [events@eortc.org](mailto:events@eortc.org).